StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report released on Tuesday. The brokerage issued a sell rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of Navidea Biopharmaceuticals stock opened at $0.00 on Tuesday. The company has a market cap of $100,080.00, a PE ratio of -0.02 and a beta of 1.46. Navidea Biopharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.13.
About Navidea Biopharmaceuticals
See Also
- Five stocks we like better than Navidea Biopharmaceuticals
- Consumer Discretionary Stocks Explained
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- How to Effectively Use the MarketBeat Ratings Screener
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Health Care Stocks Explained: Why You Might Want to Invest
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.